Skip to content

Analgesic Efficacy and Multi-Dimensional Outcomes of Bilateral Ultrasound Guided Cervical Vagus Nerve Hydrodilatation in Fibromyalgia Patients: An Exploratory Single Arm Study

Analgesic Efficacy and MultiDimensional Outcomes of Bilateral Ultrasound Guided Cervical Vagal Nerve Hydrodilatation in Fibromyalgia Patients An Exploratory Single Arm Study - TRFMPOCUSGGBLCVCNX5DWHD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/098498
Enrollment
30
Registered
2025-12-04
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M797- Fibromyalgia

Interventions

Intervention1: Point of Care Ultrasound Guided Bilateral Cervical Vagus Nerves 5 Percent Dextrose Water Hydrodilatation: 20 ml of Sterile 5 Percent Dextrose Water Injected through 22 G Sterile Hypoder

Sponsors

AIIMS Rishikesh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Diagnosed as Fibromyalgia as per 2016 ACR Revised Preliminary Clinical Criteria for FM 2 Already on Dual-Drug Therapy of Duloxetine at least 40 mg per Day and Pregabalin at least 150 mg per Day for at least 3 months continued in the same Dosages during the duration of the Study 3 Pre-Intervention Baseline WPI greater than or equal to 7 4 Pre-Intervention Baseline SSS greater than or equal to 7 5 Pre-Intervention Baseline ODI greater than or equal to 50 percent 6 Pre-Intervention Baseline PHQ-9 greater than or equal to 10 7 Undergoing Pre-Intervention Baseline as well as Day 30 not exceeding day 90 Post-intervention for Heart Rate Variability Based Autonomic Function Tests

Exclusion criteria

Exclusion criteria: 1 Patients on Anti Platelet Anti Coagulant Medication 2 Patients with any of these known Co Morbidities Uncontrolled Severe Cardiovascular Disease e.g. Severe Uncontrolled Systemic Hypertension greater than or equal to 180 90 mmHg NIBP Cardiac Dys Rhythmias with or without Implantable Pacemakers Cardioverter Defibrillators Severe Valvular heart Diseases any Causes of reduced Cardiac Ejection Fraction less than 40 percent any other Cardiovascular Disease Dysfunction qualifying as American Society of Anesthesiologists Physical Status Classification PS III or IV 3 or 4 3 Patients with Diagnosed Coagulopathy s 4 Women with Confirmed Pregnancy 5 Patients with a known observed Allergy to Ultrasound Conducting Jelly Rarely so

Design outcomes

Primary

MeasureTime frame
Magnitude of Interval Change from pre-intervention Baseline in WPI at Days 30, 60 & 90 Post-Intervention.Timepoint: Pre Intervention and at Days 30,60 & 90 Post-Intervention.

Secondary

MeasureTime frame
Magnitude of Interval Change in from pre-intervention Baseline SSS at Days 30, 60 & 90 Post-Intervention.Timepoint: Pre-Intervention & Days 30, 60 & 90 Post-Intervention.;Magnitude of Interval Change from pre-intervention Baseline in ODI at Days 30, 60 & 90 Post-Intervention.Timepoint: Pre-Intervention & Days 30, 60 & 90 Post-Intervention.;Magnitude of Interval Change from pre-intervention Baseline in PHQ-9 Score for Severity of Clinical Depression at Days 30, 60 & 90 Post-Intervention.Timepoint: Pre-Intervention & Days 30, 60 & 90 Post-Intervention.;Magnitude of Interval Change from pre-intervention Baseline in each of the Heart Rate Variability Based Tests of Autonomic Functions at Days 30, 60 & 90 post- Intervention.Timepoint: Pre-Intervention & Days 30, 60 & 90 Post-Intervention.

Countries

India

Contacts

Public ContactDr Praveen Talawar

AIIMS Rishikesh

dr.vpd.expressclinics@gmail.com7795999169

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026